BiPar Sciences' Acquisition

BiPar Sciences was acquired by Sanofi on April 15, 2009.

BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including t…

Articles about BiPar Sciences' Acquisition: